Aeterna Zentaris Inc AEZS:NASDAQ

Last Price$0.40NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$0.40 (2)
Ask (Size)$0.41 (20)
Day Low / HighN/A - N/A
Volume2.2 M
 

Read more news Recent News

--HC Wainwright Starts AEterna Zentaris at Buy With $2 Price Target
7:33AM ET 10/25/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

AEterna Zentaris Announces Sale of 6.9 Million Shares
5:40PM ET 2/16/2021 MT Newswires

AEterna Zentaris (AEZS) announced after the close on Tuesday that it has entered into an underwriting agreement with H.C. Wainwright to purchase...

After Hours Watch List Scorecard: AEZS, PLAG, TTOO
5:35PM ET 1/27/2021 MT Newswires

Here's how the stocks on Tuesday After Hours Watch List performed during today's regular session: AFTER HOURS REGULAR SESSION AEZS ...

Close Update: Stocks End Sharply Lower Amid Stimulus Worries, Record Loss at Boeing
4:57PM ET 1/27/2021 MT Newswires

US stocks closed lower on Wednesday on investor concern over a potential delay in a COVID-19 economic stimulus package and a record annual loss at Boeing...

View all Commentary and Analysis

Aeterna Zentaris: Revisiting A Past Winner
5:26PM ET 2/21/2021 Seeking Alpha

Company Profile

Business DescriptionÆterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC. View company web site for more details
Address315 Sigma Drive
Charleston, South Carolina 29486
Phone+1.843.900.3223
Number of Employees20
Recent SEC Filing11/04/20216-K
President, Chief Executive Officer & DirectorKlaus Wolfgang Paulini
Chief Financial Officer & Senior Vice PresidentLeslie Auld
Chief Scientific OfficerMichael Teifel
Chief Medical Officer & VP-Clinical DevelopmentNicola Ammer

Company Highlights

Price Open$0.44
Previous Close$0.43
52 Week Range$0.35 - 3.62
Market Capitalization$48.6 M
Shares Outstanding121.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/23/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.07
Beta vs. S&P 500N/A
Revenue$26.9 M
Net Profit Margin-156.34%
Return on Equity-13.07%

Analyst Ratings as of 10/22/2021

Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset